News articles about Bristol-Myers Squibb (NYSE:BMY) have been trending somewhat positive on Wednesday, Accern reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Bristol-Myers Squibb earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.8805233578692 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news articles that may have effected Accern Sentiment’s analysis:
- Bristol-Myers Squibb nixes 58 marketing jobs as HIV medications near patent cliff (fiercepharma.com)
- Bristol-Myers Squibb Co (NYSE:BMY) Shares Bought by Alley Co LLC (ismboard.com)
- Bristol-Myers Squibb Co (BMY) Position Maintained by Sit Investment Associates Inc (vothemes.com)
- Bristol-Myers Squibb Co (BMY) Shares Sold by Capital One National Association (famososartistas.com)
- Celldex (CLDX) Q2 Loss Narrows, Revenues Beat, Shares Up (finance.yahoo.com)
A number of research firms recently commented on BMY. BidaskClub upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research report on Tuesday, June 27th. William Blair restated an “outperform” rating on shares of Bristol-Myers Squibb in a research report on Monday, June 26th. Vetr upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $64.33 price target on the stock in a research report on Wednesday, July 26th. BMO Capital Markets lowered Bristol-Myers Squibb from a “market perform” rating to an “underperform” rating and set a $47.00 price target on the stock. in a research report on Wednesday, May 3rd. Finally, Cowen and Company set a $65.00 price target on Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Monday, July 10th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $63.33.
Bristol-Myers Squibb (BMY) traded up 0.86% on Wednesday, hitting $57.40. The stock had a trading volume of 7,675,555 shares. Bristol-Myers Squibb has a 1-year low of $46.01 and a 1-year high of $64.77. The company’s 50 day moving average is $55.55 and its 200-day moving average is $54.50. The firm has a market capitalization of $94.13 billion, a price-to-earnings ratio of 20.96 and a beta of 1.17.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The firm had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. During the same quarter in the prior year, the business earned $0.69 earnings per share. The business’s quarterly revenue was up 5.6% compared to the same quarter last year. On average, analysts forecast that Bristol-Myers Squibb will post $2.97 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, August 1st. Stockholders of record on Friday, July 7th were issued a dividend of $0.39 per share. The ex-dividend date was Wednesday, July 5th. This represents a $1.56 annualized dividend and a dividend yield of 2.72%. Bristol-Myers Squibb’s dividend payout ratio is currently 56.73%.
In other Bristol-Myers Squibb news, Director Theodore R. Samuels II bought 6,000 shares of the stock in a transaction that occurred on Wednesday, August 2nd. The shares were bought at an average price of $55.94 per share, for a total transaction of $335,640.00. Following the acquisition, the director now directly owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.23% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://sportsperspectives.com/2017/08/10/bristol-myers-squibb-nysebmy-earning-somewhat-favorable-media-coverage-study-finds.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.